La cadena de opciones muestra datos clave de las opciones de acciones de Biofrontera a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Biofrontera..

Biofrontera (NASDAQ:BFRI) Bolsa, Cadena de Opciones

Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Quantum,Computing,Concept,,Quantum,Mechanics,,Advanced,Technology,,Artificial,Intelligence,And

AMAT

BFRI

CISO

CLIK

DOCS

GLOB

HCTI

IXHL

KLRS

LGPS

ORGN

PTIX

QUBT

SATL

SPCE

TSSI

TVTX

Descubre las acciones que destacan en el premercado de EE. UU.: Quantum Computing sube tras superar expectativas, mientras otras caen.

Acciones de Quantum Computing (QUBT) se disparan un 12%; aquí están 20 acciones que se mueven en premercado

Biofrontera Inc

Press Releases

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

BFRIW

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Athira Pharma

Clearmind Medicine

Cocrystal Pharma

China Pharma Holding

Evoke Pharma

Gelteq

Impact BioMedical

IM Cannabis

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NLS Pharmaceutics

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

TherapeuticsMD

VYNE Therapeutics

cbdMD

Benchmark

Comments

Biofrontera

Biofrontera (BFRI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL